Recruiting
Phase 2

Testosterone Replacement

Sponsor:

Seattle Institute for Biomedical and Clinical Research

Code:

NCT04049331

Conditions

Hypogonadism, Male

Fatigue Syndrome, Chronic

Eligibility Criteria

Sex: Male

Age: 18 - 54

Healthy Volunteers: Not accepted

Interventions

Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED]

placebo

Study Details

Brief summary:

The overall goal of this study is to evaluate the effect of a testosterone drug called Depo-Testosterone (or 'testosterone cypionate'), an FDA-approved drug for improving fatigue, sexual function, quality of life, body composition, muscle strength, and physical activity in young cancer survivors who report fatigue and have low testosterone. Main hypothesis is that Testosterone administration in young male cancer survivors who are in remission for at least 1 year, report cancer-related fatigue and have symptomatic testosterone deficiency will be associated with greater improvements in fatigue scores compared with placebo.

Conditions

Hypogonadism, Male

Fatigue Syndrome, Chronic

Study ID

NCT04049331

Start date

Mar 22, 2021

Status verified date

Apr, 2026

Completion date

Jan 30, 2027

Anticipated

Primary completion date

Jan 30, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Male

Age: 18 - 54

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Cancer survivors who have received chemotherapy and/or radiation therapy for their cancer and are now in remission for at least one year
  • Non-hormone-dependent cancer, including most solid tumors, lymphomas and leukemias
  • Age: 18-54 years
  • Serum testosterone, measured by mass spectrometry (gold standard method), of <348 ng/dl and/or free testosterone <70 pg/ml. The lower limits of the normal range for total testosterone in healthy young men (age 19-40 years), is 348 ng/dL and the lower limits of free testosterone is <70 pg/ml in the Framingham Heart Study sample97. Therefore, young symptomatic men with total testosterone <348 ng/dl could be considered testosterone deficient. As sex hormone binding globulin levels may be elevated in some men with cancer (resulting in elevation in total testosterone level), some of these symptomatic men may still be hypogonadal despite having total testosterone above this cut-off limit. However; their free testosterone levels may still be below the lower limit of normal. Thus, we will also include men with free testosterone <70 pg/mL.
  • Self-reported fatigue. We have selected these symptoms because they are commonly reported in male cancer survivors. Fatigue will be defined as a score on Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) subscale of <40, which best divides cancer patients from the general population with 84% accuracy, and was used as the cut-off for the NIA-funded 50-million-dollar testosterone trial (The T-Trial).
  • Ability and willingness to provide informed consent.

Exclusion Criteria:

  • Men with hormone-dependent cancers (breast, prostate or adenocarcinoma of unknown origin)
  • Men with brain cancer (potential cognitive impairment)
  • Use of anabolic agents (testosterone, dehydroepiandrosterone, growth hormone) within the past 6 months
  • Appetite stimulating agents e.g. megestrol acetate within the past 6 months
  • Systemic glucocorticoids e.g. prednisone 20 mg daily or equivalent doses of other glucocorticoids for more than two weeks in the past 6 months
  • Baseline hematocrit >48%
  • PSA >4 ng/ml in Caucasians; >3 ng/ml in African-Americans
  • Men with 1st order relatives with a history of prostate cancer
  • Uncontrolled congestive heart failure
  • Severe untreated sleep apnea
  • Myocardial infarction, acute coronary syndrome, revascularization surgery, or stroke within 3 months

o Previous stroke with residual cognitive or functional deficits; Mini-Mental State Examination score <24
  • Serum creatinine >2.5 mg/dL; ALT 3x upper limit of normal
  • Poorly controlled diabetes as defined by hemoglobin A1c >8.5%; Body mass index (BMI) >45 kg/m2
  • Untreated unipolar depression (treated depression with medications or counseling will be allowed
  • Bipolar disorder or schizophrenia

Study Design

Enrollment

240 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Testosterone

Testosterone undecanoate injection 750 MG/3 ML

placebo comparator: Placebo

clinical grade saline 0.9% sodium chloride injection

Interventions

Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED]

first two doses four weeks apart; following three more doses every ten weeks.

placebo

first two doses four weeks apart; following three more doses every ten weeks.

Primary outcome measure

  • Fatigue change [ Time Frame: 9 months ]

Central Contacts and Locations

Central contacts

Jose M Garcia, MD, PhD

206 764 2984jg77@uw.edu

Locations

Brigham and Women's Hospital

Recruiting

Boston, Massachusetts, United States, 02115

Contacts

Milena Braga, MD

617-525-9144mbraga@bwh.harvard.edu

Principal Investigator:

Shehzad Basaria, MD

Veterans Affairs Puget Sound Health Care System

Recruiting

Seattle, Washington, United States, 98108

Contacts

Gary Miranda, LPN

2062776143Gary.Miranda@va.gov

Lindsey Anderson, PhD

2062776719Lindsey.Anderson5@va.gov

Principal Investigator:

Jose M Garcia, MD, PhD

More Information

Sponsor

Seattle Institute for Biomedical and Clinical Research

Last update posted

Jun 22, 2026

Last verified

Apr, 2026

Keywords

  • testosterone
  • hypogonadism
  • cancer related fatigue

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-21. This information was provided to ClinicalTrials.gov by Seattle Institute for Biomedical and Clinical Research on 2026-06-22.